Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Inclusion Criteria:

• Adult male and female subjects of ages in the range over 19

• The subjects HBsAg positive for at least 6 months or has history of ChronicHepatitis B

• The subjects whose HBV DNA above 20,000 IU/mL when HBeAg positive or above 2,000IU/mL when HBeAg negative or positive when has history of Chronic Hepatitis B

• The subjects completely understood the clinical trial through detailed explanationpresented, determined to participate in the clinical trial spontaneously, and agreedto observe precautions suggested thereby through written consent

Exclusion Criteria:

• The subjects who have been infected with HCV, HDV, HIV

• The subjects who have Hemochromatosis, Wilson's disease, autoimmune liver disease,and α-1 antitrypsin deficiency

• The subjects whose α-fetoprotein over 50 ng/mL and who are persumed to beHepatocelluar carcinoma